WuXi XDC and BioDlink successfully hosted the 2026 Open Day, unveiling a new era for bioconjugate therapies through collaboration.

BioDlink has been awarded 'Emerging CDMO of the Year,' recognizing its innovation in biologics and ADC development through advanced technology and quality systems.

BioDlink has been named “Emerging CDMO of the Year” for its innovation in complex biologics and ADC development. The award recognizes its proprietary technology platforms, scalable manufacturing, and a proven quality system with over 100 audits completed. SUZHOU, China, March 13, 2026 /PRNewswire/ — BioDlink, an innovation-driven Contract Development and Manufacturing Organization (CDMO), today announced […]

Suzhou, China (ANTARA) – BioDlink Biopharm Co., Ltd. menorehkan pencapaian penting dengan lolos inspeksi sertifikasi Good Manufacturing Practice (GMP) ...

BioDlink has been honored by Chengdu Kanghong Pharmaceutical for its role in the development of the world's first dual-payload ADC, advancing clinical trials ahead of schedule.

BioDlink has successfully integrated Veeva QMS into its operations, enhancing quality management and compliance processes, ensuring dynamic evolution in its service delivery.

BioDlink showcases its pivotal role in biopharmaceuticals at Biologics CDMO Europe 2025, marking a significant advancement in global collaboration.

BioDlink and Lepu Biopharma mark a significant milestone with the launch of MEIYOUHENG®, the first EGFR-targeting ADC drug, showcasing their collaborative achievement in biologics.

BioDlink congratulates Lepu Biopharma for the historic approval of the world's first EGFR-targeted ADC, revolutionizing treatment for cancer patients.

BioDlink's first international shipment of Bevacizumab injection to Colombia marks a significant advancement in targeted cancer therapy.

BioDlink's Bevacizumab Injection has been approved in Indonesia, marking a significant step in their global expansion and enhancing patient access to vital treatments.

BioDlink accelerates its global growth with successful bevacizumab launches in Colombia and Pakistan, striving to enhance oncology treatment access.

Discover how BioDlink is spearheading global biopharmaceutical advancement through collaboration and innovation in the biotech ecosystem.

BioDlink's Bevacizumab Injection has received marketing authorization in Nigeria, boosting its global footprint. The approval addresses urgent healthcare needs in Africa.

BioDlink Biopharm has obtained GMP certification from Argentina, enhancing its global presence and commitment to oncological therapies with Pusintin® injection.

BioDlink's successful GMP audit in Brazil marks a significant milestone in its expansion into emerging markets, particularly in oncology treatments. This approval strengthens its commitment to quality.

BioDlink proudly announces Junshi Biosciences' IND approval for JS212, a bispecific ADC aimed at treating various cancers. This milestone showcases advanced therapeutic advancements.

WuXi XDC and BioDlink jointly hosted the 2026 Open Day, marking their first flagship customer-facing event following the strategic integration. The event brought together biotech customers, industry leaders and innovators to explore how an integrated ADC/XDC CRDMO platform can accelerate...

BioDlink has been named "Emerging CDMO of the Year" for its innovation in complex biologics and ADC development. The award recognizes its proprietary technology platforms, scalable manufacturing, and a proven quality system with over 100 audits completed. SUZHOU, China, March 13, 2026...

Recognized as Biologics CDMO of the Year, BioDlink shares insights into the world's first approved EGFR-targeted ADC for recurrent/metastatic nasopharyngeal carcinoma The company enables seamless Europe–China tech transfer and faster biologics development through an integrated, end-to-end...

Celebrating a Shared Milestone: BioDlink and Lepu Biopharma celebrated the launch of MEIYOUHENG®, the world's first EGFR-Targeting ADC, and their partnership spanning over two years. Demonstrating Robust Capabilities: Throughout the collaboration, all technology transfers and GMP...

BioDlink helps Lepu Biopharma win China's marketing approval for EGFR-targeted ADC treating recurrent or metastatic nasopharyngeal carcinoma This Becotatug Vedotin injection approval is BioDlink's first commercial ADC manufacturing initiative worldwide, validating its complex biologics...

Bevacizumab is a targeted therapy used to treat lung and colorectal cancers, both among the top three cancers ranked by death in Colombia [1] . This inaugural shipment— dispatched around two months after Colombia's marketing approval — demonstrates the company's efficiency, while...

- BioDlink's bevacizumab injection secures marketing authorization in Colombia and Pakistan following its recent approval in Nigeria, marking key regulatory milestones in high-need emerging markets. - GMP certification in Brazil, Colombia, and Argentina spans the top three most populous...